FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386001286> ?p ?o ?g. }

• W4386001286 endingPage "1845" @default.
• W4386001286 startingPage "1832" @default.
• W4386001286 abstract "Glucagon-like peptide-1 receptor agonists (GLP-1RAs, incretin mimetics) and dipeptidyl peptidase-4 inhibitors (DPP-4is, incretin enhancers) are glucose-lowering therapies with proven cardiovascular safety, but their effect on microvascular disease is not fully understood. Both therapies increase GLP-1 receptor agonism, which is associated with attenuation of numerous pathological processes that may lead to microvascular benefits, including decreased reactive oxygen species (ROS) production, decreased inflammation and improved vascular function. DPP-4is also increase stromal cell-derived factor-1 (SDF-1), which is associated with neovascularisation and tissue repair. Rodent studies demonstrate several benefits of these agents in the prevention or reversal of nephropathy, retinopathy and neuropathy, but evidence from human populations is less clear. For nephropathy risk in human clinical trials, meta-analyses demonstrate that GLP-1RAs reduce the risk of a composite renal outcome (doubling of serum creatinine, eGFR reduction of 30%, end-stage renal disease or renal death), whereas the benefits of DPP-4is appear to be limited to reductions in the risk of albuminuria. The relationship between GLP-1RAs and retinopathy is less clear. Many large trials and meta-analyses show no effect, but an observed increase in the risk of retinopathy complications with semaglutide therapy (a GLP-1RA) in the SUSTAIN-6 trial warrants caution, particularly in individuals with baseline retinopathy. Similarly, DPP-4is are associated with increased retinopathy risk in both trials and meta-analysis. The association between GLP-1RAs and peripheral neuropathy is unclear due to little trial evidence. For DPP-4is, one trial and several observational studies show a reduced risk of peripheral neuropathy, with others reporting no effect. Evidence in other less-established microvascular outcomes, such as microvascular angina, cerebral small vessel disease, skeletal muscle microvascular disease and autonomic neuropathies (e.g. cardiac autonomic neuropathy, gastroparesis, erectile dysfunction), is sparse. In conclusion, GLP-1RAs are protective against nephropathy, whereas DPP-4is are protective against albuminuria and potentially peripheral neuropathy. Caution is advised with DPP-4is and semaglutide, particularly for patients with background retinopathy, due to increased risk of retinopathy. Well-designed trials powered for microvascular outcomes are needed to clarify associations of incretin therapies and microvascular diseases." @default.
• W4386001286 created "2023-08-20" @default.
• W4386001286 creator A5038288835 @default.
• W4386001286 creator A5064711940 @default.
• W4386001286 creator A5084593004 @default.
• W4386001286 date "2023-08-19" @default.
• W4386001286 modified "2023-10-12" @default.
• W4386001286 title "Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy" @default.
• W4386001286 cites W1836662115 @default.
• W4386001286 cites W1963662494 @default.
• W4386001286 cites W1969759659 @default.
• W4386001286 cites W1977093725 @default.
• W4386001286 cites W1977559795 @default.
• W4386001286 cites W1989453119 @default.
• W4386001286 cites W1992116679 @default.
• W4386001286 cites W1994369811 @default.
• W4386001286 cites W1995209325 @default.
• W4386001286 cites W2014159843 @default.
• W4386001286 cites W2021058979 @default.
• W4386001286 cites W2021375788 @default.
• W4386001286 cites W2034721778 @default.
• W4386001286 cites W2040913747 @default.
• W4386001286 cites W2044685101 @default.
• W4386001286 cites W2048765055 @default.
• W4386001286 cites W2056405400 @default.
• W4386001286 cites W2059736408 @default.
• W4386001286 cites W2064130493 @default.
• W4386001286 cites W2067407883 @default.
• W4386001286 cites W2067506867 @default.
• W4386001286 cites W2069460375 @default.
• W4386001286 cites W2072750268 @default.
• W4386001286 cites W2074344799 @default.
• W4386001286 cites W2074756738 @default.
• W4386001286 cites W2081559121 @default.
• W4386001286 cites W2116831537 @default.
• W4386001286 cites W2126528640 @default.
• W4386001286 cites W2127854619 @default.
• W4386001286 cites W2128591799 @default.
• W4386001286 cites W2129730863 @default.
• W4386001286 cites W2142097676 @default.
• W4386001286 cites W2142226770 @default.
• W4386001286 cites W2142830692 @default.
• W4386001286 cites W2148122132 @default.
• W4386001286 cites W2153008086 @default.
• W4386001286 cites W2156280702 @default.
• W4386001286 cites W2158498099 @default.
• W4386001286 cites W2172204314 @default.
• W4386001286 cites W2220062488 @default.
• W4386001286 cites W2335799633 @default.
• W4386001286 cites W2346900324 @default.
• W4386001286 cites W2400673520 @default.
• W4386001286 cites W2413263575 @default.
• W4386001286 cites W2414651678 @default.
• W4386001286 cites W2425644022 @default.
• W4386001286 cites W2492755821 @default.
• W4386001286 cites W2517060465 @default.
• W4386001286 cites W2519510391 @default.
• W4386001286 cites W2534221266 @default.
• W4386001286 cites W2581527741 @default.
• W4386001286 cites W2599730432 @default.
• W4386001286 cites W2607405121 @default.
• W4386001286 cites W2609340129 @default.
• W4386001286 cites W2743808201 @default.
• W4386001286 cites W2769264260 @default.
• W4386001286 cites W2782819059 @default.
• W4386001286 cites W2785139619 @default.
• W4386001286 cites W2789501881 @default.
• W4386001286 cites W2794652074 @default.
• W4386001286 cites W2800981650 @default.
• W4386001286 cites W2803540340 @default.
• W4386001286 cites W2900149048 @default.
• W4386001286 cites W2913797456 @default.
• W4386001286 cites W2916320147 @default.
• W4386001286 cites W2949434037 @default.
• W4386001286 cites W2963323248 @default.
• W4386001286 cites W2989595138 @default.
• W4386001286 cites W3008946147 @default.
• W4386001286 cites W3014755863 @default.
• W4386001286 cites W3015967596 @default.
• W4386001286 cites W3032993523 @default.
• W4386001286 cites W3036137488 @default.
• W4386001286 cites W3087450863 @default.
• W4386001286 cites W3114565741 @default.
• W4386001286 cites W3165600686 @default.
• W4386001286 cites W3176374233 @default.
• W4386001286 cites W3182324895 @default.
• W4386001286 cites W3183842190 @default.
• W4386001286 cites W3186065500 @default.
• W4386001286 cites W3189903781 @default.
• W4386001286 cites W3194272436 @default.
• W4386001286 cites W3203899748 @default.
• W4386001286 cites W4200181543 @default.
• W4386001286 cites W4200549529 @default.
• W4386001286 cites W4210321112 @default.
• W4386001286 cites W4211100132 @default.
• W4386001286 cites W4223515927 @default.
• W4386001286 cites W4235291177 @default.
• W4386001286 cites W4283816664 @default.

• next